key: cord-0933112-8jyl9m4a authors: Ramey, Olivia L.; Silva Almodóvar, Armando; Nahata, Milap C. title: Medication Adherence in Medicare Enrolled Older Adults with Asthma Before and During the COVID-19 Pandemic date: 2022-02-25 journal: Ann Allergy Asthma Immunol DOI: 10.1016/j.anai.2022.02.010 sha: 145e76ff2da8ea7a2b872f446d5cb7713809f89e doc_id: 933112 cord_uid: 8jyl9m4a Background Data regarding medication adherence in older adults with asthma before and during the COVID-19 pandemic is lacking. Objective To evaluate medication adherence and determine factors associated with adherence in Medicare enrolled older adults with asthma before and during the COVID-19 pandemic. Methods This was a retrospective cohort analysis of Medicare enrolled patients with asthma. Medication adherence was measured using proportion of days covered (PDC) rates for dates January-July 2019 and January-July 2020. Patients <65 years of age, with chronic obstructive pulmonary disease, or cystic fibrosis were excluded. Paired t-tests assessed change in adherence between 2019 and 2020. Logistic regression evaluated association of age, sex, depression, moderate/severe asthma, use of a 90-days’ supply, having ≥3 albuterol fills, and number of medications, medication-related problems, prescribers, pharmacies, controller medication classes, and systemic corticosteroid fills with high adherence (PDC ≥80%). Results Mean adherence to asthma controller medications ranged from 75-90%, in 2019. Adherence significantly decreased (p<0.001) to 51-70% for all controller medications, except theophylline in 2020. Similar results were observed among patients with moderate/severe asthma. In 2019 and 2020, number of controller medications, ≥3 albuterol fills, and having a 90 days’ supply were associated with high adherence (p<0.001). Conclusion Adherence to asthma controller medications significantly decreased during the COVID-19 pandemic among Medicare enrolled patients with asthma. Patients with markers for more severe asthma, overuse of albuterol, and a 90-day supply of controller medications were more likely to have high adherence. These findings can be used to identify opportunities to improve adherence and prescribing among adult patients with asthma. Background: Data regarding medication adherence in older adults with asthma before and during the COVID-19 pandemic is lacking. Objective: To evaluate medication adherence and determine factors associated with adherence in Medicare enrolled older adults with asthma before and during the COVID-19 pandemic. This was a retrospective cohort analysis of Medicare enrolled patients with asthma. Medication adherence was measured using proportion of days covered (PDC) rates for dates January-July 2019 and January-July 2020. Patients <65 years of age, with chronic obstructive pulmonary disease, or cystic fibrosis were excluded. Paired t-tests assessed change in adherence between 2019 and 2020. Logistic regression evaluated association of age, sex, depression, moderate/severe asthma, use of a 90-days' supply, having ≥3 albuterol fills, and number of medications, medication-related problems, prescribers, pharmacies, controller medication classes, and systemic corticosteroid fills with high adherence (PDC ≥80%). Mean adherence to asthma controller medications ranged from 75-90%, in 2019. Adherence significantly decreased (p<0.001) to 51-70% for all controller medications, except theophylline in 2020. Similar results were observed among patients with moderate/severe asthma. In 2019 and 2020, number of controller medications, ≥3 albuterol fills, and having a 90 days' supply were associated with high adherence (p<0.001). Adherence to asthma controller medications significantly decreased during the COVID-19 pandemic among Medicare enrolled patients with asthma. Patients with markers for more severe asthma, overuse of albuterol, and a 90-day supply of controller medications were more likely to have high adherence. These findings can be used to identify opportunities to improve adherence and prescribing among adult patients with asthma. Asthma and other chronic lower respiratory conditions were the fourth leading cause of death in the United States (US) in 2019. 1 Annual costs related to asthma were estimated to be nearly $80 billion in the US, according to data collected from 2008-2013. 2 Older adults with asthma have an increased risk of morbidity and mortality compared with younger adults. [3] [4] [5] The use of asthma controller medications is necessary to reduce inflammation and prevent airway constriction among patients with asthma. One study found significant underutilization of controller medications for asthma control among recently hospitalized older adults in a Medicaid program. 6 Another study reported approximately 80% of adults with moderate to severe asthma were not fully adherent to their inhaled corticosteroids. 7 Serhal et al. 8 observed 72% of adults with asthma had not started using or were considered nonadherent to their controller medications. Systematic reviews of studies in both adult and pediatric populations have found higher rates of adherence to be generally associated with fewer asthma exacerbations despite several studies noting positive or null associations between adherence and exacerbations. [9] [10] [11] However, while one study found older adults with any respiratory condition were with an average medication possession ratio of approximately 25% for fluticasone/salmeterol inhalers, 12 rates of adherence to controller medications are unknown among older adults with asthma. The coronavirus disease-19 (COVID-19) pandemic created unexpected life-changing disruptions, potentially affecting access to healthcare services including access and utilization of medications for asthma. 13 There are no data, however, on the influence of the COVID-19 pandemic on medication adherence in older adults with asthma. The primary objectives of this investigation were: (1) to examine medication prescribing and adherence among older adult Medicare eligible patients with asthma; (2) to determine the impact of the COVID-19 pandemic on medication adherence; and (3) to evaluate the associations of patient characteristics with medication adherence in older adults with asthma. This was a retrospective, longitudinal cohort analysis of Medicare enrolled patients with asthma. Patients with International Statistical Classification of Diseases and Related Health Problems 9 th (ICD-9) or 10 th revisions (ICD-10) codes for asthma in 2019 (eTable 1) were included. Patients under 65 years of age or with diagnosis codes for chronic obstructive pulmonary disease or cystic fibrosis were excluded (eTable 1). Patients were included in this analysis if they had at least 2 prescription claims for the same controller medication. Controller medications assessed in this study were inhaled corticosteroids (ICS), long-acting beta agonists (LABA), long-acting muscarinic antagonists (LAMA), leukotriene receptor antagonists (LRA), and theophylline (eTable 2). This study was approved by the Institutional Review Board as a retrospective record review (Approved 09/22/2020, Study ID: 2020H0393). Patients included in this study were enrolled in one Medicare plan and eligible for medication therapy management (MTM) services for the years 2019 and 2020. Eligibility for MTM services was dependent on presence of certain chronic conditions, total number of unique medications, and annual drug cost exceeding a specific value. 14 Eligibility was determined by the health plan provider. Prescription claims data range from January 1, 2019, to July 31, 2019, and January 1, supply, and fill count), and the proportion of days covered (PDC) for controller medications by medication class (eTable 2). MRPs reflected potential problems related to drug-drug interactions, drug disease interactions, the use of high-risk medications, gaps in therapy, and medication adherence to therapies for specific chronic diseases identified in the electronic prescription claims data. Adherence was evaluated for asthma controller medication classes for a fixed period of January 1 -July 31, 2019, and January 1 -July 31, 2020. Medications assessed in this study were only those for which claims were processed under Medicare Part D. Biologic medications were not included because those claims are mostly processed under Medicare Part B. The list of medications assessed by class can be found in eTable 2. PDC was utilized to compare adherence to controller medications between the 2019 and 2020 evaluation period. 15 The PDC reflected the percentage of days a person had access to a medication within a specific period. The numerator was the sum of days a medication within a medication class was available to the patient with the start date beginning at the date of the first prescription. The denominator was the number of days between the first fill and the analysis end date. PDC was reported by medication class to avoid underestimation of adherence when prescribing of medications within the same therapeutic class was modified due to dose or formulary changes. High adherence was defined as PDC ≥80%. This analysis included 1,637 patients. Patients were 76± 7 standard deviation (SD) years of age, with 7± 3 SD prescribers in the first seven months of 2019, used 3± 2 SD pharmacies to fill medications, and were prescribed 13± 4 SD medications. Patients were predominantly female (1356, 83%). In this cohort, 624 (38%) were diagnosed with moderate or severe asthma and 329 (20%) with depression. Most patients utilized ≥2 controller medication classes for asthma (1252, 76%), filled ≥3 albuterol inhalers (1102, 67%), and did not require corticosteroids (971, 59%) in the first seven months of 2019. Complete information can be found in Table 1 . More than one-half of patients were considered highly adherent to their controller medications (ICS (64%), LABA (63%), LAMA (73%), LRA (81%), and theophylline (63%)) in 2019. In the first seven months of 2020, during the COVID-19 pandemic, the proportion of patients considered highly adherent decreased (ICS (52%), LABA (51%), LAMA (46%), montelukast (64%), and theophylline (44%)). Mean PDC, indicated by the filling of ICS, LABA, LAMA, and LRA, significantly decreased between 2019 and 2020 (p<0.001). Due to an adjusted Bonferroni p value, mean PDC did not significantly change for theophylline between 2019 and 2020 (p>0.005). While the mean adherence was higher, and the proportion of patients considered highly adherent was greater, similar results were observed among patients diagnosed with moderate to severe asthma. Complete medication use data appear in Table 2 . Table 3 includes complete information and lists nonsignificant variables. To our knowledge, this is the first study to examine medication adherence and prescribing patterns among Medicare-enrolled, MTM-eligible older adults with asthma before and during the first months of the COVID-19 pandemic. This study found a significant reduction in adherence to controller medications for asthma in the first seven months of 2020. Important indicators for adherence to controller medications between 2019 and 2020 were surrogate markers for disease severity (number of controller medication classes for asthma and number of albuterol inhalers) and having filled a 90-day supply for a controller medication. These findings suggested access to controller medications for patients with asthma may have been interrupted during the early months of the COVID-19 pandemic. Our data showed that the proportion of patients considered highly adherent to specific controller medications ranged from 63-81% in 2019 and 44-64% in 2020. Patients in this cohort were with higher adherence compared to the results of a survey where 43% of older adults with asthma reported they were with good adherence 16 and another study that found older adults with any respiratory condition were on average with a calculated adherence of 25% of their fluticasone/salmeterol inhaler. 12 The COVID-19 pandemic may have resulted in barriers to medication adherence due to many factors including fears of infection, delays among mail order pharmacies, drug shortages, and disruptions to continuity of care. Healthcare providers and insurance plans should prioritize 90-days' supply of controller medications to improve adherence to these medications by reducing disruptions of access during disaster events such as the COVID-19 pandemic. Patients in this cohort treated with a greater number of controller medication classes were more likely to be highly adherent to their medications. These findings are consistent with the health belief model that describes a patient's greater perception of illness to be associated with higher adherence. 17 Another study found changes in medication adherence during the COVID-19 pandemic varied across different medication classes. 18 It is important for providers to identify barriers to medication adherence and to emphasize the importance of controller medications given their role in preventing avoidable healthcare utilization among patients with asthma. Furthermore, a recent study found use of medications to treat asthma were associated with better outcomes among patients with asthma and COVID-19, reinforcing the importance of adherence in this vulnerable population. 19 Notably, patients with high adherence in 2019 were more likely to be highly adherent in 2020 suggesting once patients are adherent to their therapies, this behavior is more likely to be sustained among patients with asthma. It is also important to highlight this study found 67% of patients in 2019 and 60% of patients in 2020 were with ≥3 albuterol fills in the first seven months of each year. This suggested that regardless of rates of adherence to controller medications, patients were potentially overutilizing albuterol to ameliorate symptoms associated with asthma, placing them at risk for possible avoidable healthcare utilization including emergency room visits and hospitalizations, and higher cost of care. [20] [21] [22] [23] Overuse of SABA medications can lead to betareceptor downregulation, causing decreased response to SABA treatment and rebound bronchoconstriction. 24 In turn, SABA overuse causes a patient to consume even more reliever treatment as it becomes less effective. While a recent study found asthma related emergency room visits and hospitalizations decreased overall among all patients with asthma during the COVID-19 pandemic, potentially due to social distancing and face mask wearing, 25 the targeted identification of patients with potential overutilization of SABA inhalers can improve medication utilization, quality of life, and reduce potentially avoidable healthcare utilization in this cohort. Patients with more MRPs in this study were less likely to be adherent to their medications in 2019. Patients participating in programs that identify and address MRPs may experience improved compliance to the overall medication regimen. These patients may benefit from programs that utilize a combination of education and inhaler coaching from an asthma educator and regular, long-term follow up with pharmacists; an intervention that demonstrated reduced emergency department utilization, hospitalization, and direct cost savings. 26 Additionally, a pharmacist-led intervention dedicated to improving asthma medication use was associated with reductions in exacerbations, improved asthma symptom control and quality of life, and improved adherence to prescribed treatment. 27 While surrogate markers for disease severity such as number of controller medication classes and albuterol fills were consistently associated with medication adherence in 2019 and 2020, corticosteroids were not. This relationship may not have been consistently detected because oral corticosteroids may have been utilized for other diseases. It is important for prescribers and providers to highlight the preventative benefits of asthma controller medications to reduce avoidable healthcare utilization. The population of this study was limited to Medicare-enrolled, MTM-eligible beneficiaries from one insurance plan provider, and thus may not be representative of an entire Medicare population nor represent a geographically diverse population. Adherence during the COVID-19 pandemic may have been underestimated due to the study period examining the first 7 months of 2020. Investigators were unable to assess if adherence was influenced by shortages affecting the supply of available medications in dispensing pharmacies. We were unable to determine if rescue inhalers claims were the result of patient stockpiling or early refills related to travel. Adherence measurements were based on prescription claims data; investigators were unable to assess if patients used the medications as prescribed. Investigators were unable to assess the influence of patient co-pay on adherence outcomes or the effect of using mail order pharmacies on adherence. The MRPs included in this study were those determined by electronic review of prescription claims, which may differ from MRPs identified by other approaches. Investigators were unable to assess for the effects of a covid infection on adherence. Older adults with asthma represent an understudied patient population. In 2019, among Medicare enrolled older adults, mean adherence ranged from 75%-90% depending on the controller medication. Results from our data suggested that medication adherence may have been negatively impacted by the COVID-19 pandemic.. Despite the significant decrease in adherence to asthma controller medications, patients continued filling SABA inhalers at a similar rate, suggesting older adults may be over-reliant on SABA reliever inhalers for treatment of asthma. Patients with more controller medications, more albuterol fills, and a 90-days' supply were more likely to be highly adherent to their controller medications. Healthcare providers should consistently assess barriers to medication adherence and albuterol use to ensure optimal control of asthma. Patients may benefit from 90-days' supply of controller medications to reduce disruptions in access, especially during epidemics or pandemics. Lower Respiratory Disease The Economic Burden of Asthma in the United States An Official American Thoracic Society Workshop Report: Evaluation and Management of Asthma in the Elderly Age-Related Differences in the Rate, Timing, and Diagnosis of 30-Day Readmissions in Hospitalized Adults With Asthma Exacerbation Age-related differences in clinical outcomes for acute asthma in the United States Underutilization of controller and rescue medications among older adults with asthma requiring hospital care Relationship of Inhaled Corticosteroid Adherence to Asthma Exacerbations in Patients with Moderate-to-Severe Asthma Medication Adherence in a Community Population with Uncontrolled Asthma. Pharmacy (Basel) Medication adherence and the risk of severe asthma exacerbations: a systematic review Association between adherence and severe asthma exacerbation: A systematic review and meta-analysis Asthma inhaler adherence determinants in adults: systematic review of observational data Adherence and persistence with fluticasone propionate/salmeterol combination therapy Prescription Fills for Inhalers Drop as U.S. Faces Medication Shortages. GoodRx CY 2021 Medication Therapy Management Program Guidance and Submission Instructions. Centers for Medicare and Medicaid Navigating the Wild West of Medication Adherence Reporting in Specialty Pharmacy Asthma beliefs are associated with medication adherence in older asthmatics Health beliefs, disease severity, and patient adherence: a meta-analysis Patient access to chronic medications during the COVID-19 pandemic: Evidence from a comprehensive dataset of US insurance claims Asthma Disease Status, COPD, and COVID-19 Severity in a Large Multiethnic Population Short-acting β-agonist use and its ability to predict future asthma-related outcomes Overuse of short-acting β2-agonists in asthma is associated with increased risk of exacerbation and mortality: a nationwide cohort study of the global SABINA programme Usage Patterns of Short-Acting β2-Agonists and Inhaled Corticosteroids in Asthma: A Targeted Literature Review Asociación entre la utilización de broncodilatadores de corta duración y el riesgo de hospitalización por asma en condiciones de práctica clínica habitual en una cohorte poblacional [Association between the use of short-acting bronchodilators and the risk of hospitalization for asthma in a real-life Bronchodilator tolerance and rebound bronchoconstriction during regular inhaled betaagonist treatment National decline in asthma exacerbations in United States during coronavirus disease 2019 pandemic The Asheville Project: long-term clinical, humanistic, and economic outcomes of a community-based medication therapy management program for asthma We acknowledge Jacques Turgeon BPharm PhD and Dana Filippoli MBE MPH for their review and editorial contributions to the manuscript.